Range Financial Group LLC Buys Shares of 56,499 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Range Financial Group LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 56,499 shares of the company's stock, valued at approximately $797,000.

A number of other hedge funds have also recently made changes to their positions in TEVA. Charles Schwab Investment Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 8.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 686,412 shares of the company's stock worth $7,001,000 after purchasing an additional 52,436 shares during the period. Rhumbline Advisers boosted its position in Teva Pharmaceutical Industries by 12.6% in the 3rd quarter. Rhumbline Advisers now owns 299,000 shares of the company's stock valued at $3,050,000 after buying an additional 33,436 shares during the period. DekaBank Deutsche Girozentrale boosted its position in Teva Pharmaceutical Industries by 5.2% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 66,621 shares of the company's stock valued at $670,000 after buying an additional 3,281 shares during the period. FMR LLC boosted its position in Teva Pharmaceutical Industries by 3,553.8% in the 3rd quarter. FMR LLC now owns 2,564,339 shares of the company's stock valued at $26,156,000 after buying an additional 2,494,156 shares during the period. Finally, Hsbc Holdings PLC boosted its position in Teva Pharmaceutical Industries by 50.0% in the 3rd quarter. Hsbc Holdings PLC now owns 466,209 shares of the company's stock valued at $4,773,000 after buying an additional 155,388 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Vikki L. Conway sold 15,219 shares of the business's stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Roberto Mignone sold 519,000 shares of the business's stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Vikki L. Conway sold 15,219 shares of the business's stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Over the last three months, insiders have sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 2.8 %

NYSE:TEVA traded down $0.48 during midday trading on Monday, hitting $16.49. 7,562,642 shares of the company were exchanged, compared to its average volume of 10,519,361. The company has a fifty day simple moving average of $15.72 and a 200 day simple moving average of $13.52. Teva Pharmaceutical Industries Limited has a fifty-two week low of $7.42 and a fifty-two week high of $17.69. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $18.67 billion, a PE ratio of -40.21, a price-to-earnings-growth ratio of 1.63 and a beta of 0.91.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.03). The business had revenue of $3.82 billion during the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. As a group, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of several recent research reports. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a research report on Friday, March 8th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 20th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, June 5th. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 price objective (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Finally, Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Thursday, May 30th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $15.88.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.